Cortalix
Groningen, NetherlandsWebsite
Cortalix specializes in nanobody technology and molecular imaging for advanced diagnostics and targeted therapeutic applications.
2open roles
Loading company information...
Cortalix specializes in nanobody technology and molecular imaging for advanced diagnostics and targeted therapeutic applications.
Company context
Cortalix prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
Cortalix is a biotechnology company based in Groningen, Netherlands, specializing in the discovery, engineering, and development of single-domain antibodies, commonly known as nanobodies or VHH. Founded in 2023, the company leverages a proprietary platform that integrates synthetic and immune libraries to provide animal-free antibody solutions. Their work is primarily focused on advancing molecular imaging, targeted radiotherapy, and immunotherapy, with a specific emphasis on addressing fibrotic diseases and cancers. Operating at the intersection of diagnostics and therapeutics, Cortalix employs a 'theranostic' approach, where the same nanobody molecule can be utilized for both patient identification and targeted treatment. The company supports its mission through three core pillars: internal clinical development programs, collaborative research partnerships, and specialized fee-for-service offerings such as antibody humanization and engineering. By maintaining strong ties with the University of Groningen and the University Medical Center Groningen, Cortalix remains at the forefront of biomedical innovation in the Northern Netherlands.
Cortalix's mission is to leverage modern, affordable, and animal-free nanobody library technology to develop next-generation diagnostics, therapeutics, and bio-analytical tools, supporting scientific innovation through expertise in single-domain antibodies.
Founded
2023
Headquarters
Groningen, Netherlands
Employees
1-10
Industry
Biotechnology
Opportunity to work at the cutting edge of nanobody and theranostic technology
Strong integration with academic and medical research ecosystems
Early-stage startup environment may involve high pressure and limited resources
Limited organizational structure compared to established pharmaceutical firms
Funding
€1 million